<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687176</url>
  </required_header>
  <id_info>
    <org_study_id>APL003</org_study_id>
    <nct_id>NCT04687176</nct_id>
  </id_info>
  <brief_title>Frontline Oral Arsenic Trioxide for APL</brief_title>
  <official_title>Frontline Oral Arsenic Trioxide-based Induction in Newly Diagnosed Acute Promyelocytic Leukaemia in Adults - a Multicentre Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have formulated an oral preparation of As2O3 (oral-As2O3), and shown that&#xD;
      it is efficacious for APL in R1, inducing CR2 in more than 90% of patients [8,9].&#xD;
      Furthermore, in an effort to prevent relapse, the investigators have moved oral-As2O3 forward&#xD;
      to the maintenance of CR1. This strategy results in favorable overall-survival (OS) and&#xD;
      leukemia-free-survival (LFS) [10], implying that prolonged treatment with oral-As2O3 may&#xD;
      prevent relapses.&#xD;
&#xD;
      Current protocols have incorporated i.v.-As2O3 in the treatment of newly-diagnosed APL&#xD;
      [11-15]. For regimens comprising As2O3, ATRA and chemotherapy, 5-year OS in excess of 90% is&#xD;
      achieved [11-15].&#xD;
&#xD;
      The investigators have also published long-term data showing the use of oral-As2O3 is highly&#xD;
      effective and safe in the relapsed and frontline settings [16,17].&#xD;
&#xD;
      In this study, the investigators evaluate the use of oral-As2O3 and ATRA based induction&#xD;
      regimens in newly diagnosed patients with APL with no of minimal chemotherapy in a&#xD;
      prospective multicentre phase 2 study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After initial eligibility screening, patients will be recruited to oral arsenic trioxide,&#xD;
      all-trans-retinoic acid, ascorbic acid (AAA) based-induction for 42 days. Daunorubicin&#xD;
      (50mg/m^2/day for 3 days) will only be used during induction in patients &lt;65 with presenting&#xD;
      white blood cell count (WBC) ≥ 10 x 10^9/L. In patients not receiving daunorubicin,&#xD;
      hydroxyurea (2-4g/day) if WBC ≥ 5 x 10^9/L within the first 14 days of induction. Molecular&#xD;
      monitoring monitoring with RQ-PCR or ddPCR for PML-RARA will be performed weekly during&#xD;
      induction. A reassessment bone marrow aspirate will be performed on day 28 of induction for&#xD;
      assessment of morphologic remission.&#xD;
&#xD;
      Four weeks after the completion of induction phase, all patients, regardless of initial WBC,&#xD;
      will receive two cycles of chemotherapy-free AAA consolidation (14 days every 28 days).&#xD;
&#xD;
      Four weeks after completion of consolidation, all patients will receive 12 cycles of&#xD;
      chemotherapy-free AAA maintenance (14 days every 8 week).&#xD;
&#xD;
      Molecular monitoring monitoring with RQ-PCR or ddPCR for PML-RARA will be performed during&#xD;
      every 4 weeks during consolidation, every 8 weeks during maintenance, and every 3 months for&#xD;
      24 months after completion of maintenance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>60 months</time_frame>
    <description>Defined as the time (in months) from first complete morphologic remission (CR1) to morphologic or molecular relapse (event), or latest follow-up (censored).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>60 months</time_frame>
    <description>Defined as the time (in months) from recruitment to treatment failure (event), morphologic or molecular relapse (event), or latest follow-up (censored).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>60 months</time_frame>
    <description>Defined as time (in months) from diagnosis to death (event) or latest follow-up (censored).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment toxicities</measure>
    <time_frame>60 months</time_frame>
    <description>Treatment toxicities by Common Toxicity Criteria for Adverse Everts (CTCAE) version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m^2 per day in 2 divided doses) and Ascorbic acid 1g daily for 42 days Consolidation: ral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m^2 per day in 2 divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles.&#xD;
Maintenance: Oral Arsenic trioxide 10mg daily, ATRA (45mg/m^2 per day in 2 divided doses) and ascorbic acid 1g daily for 2 weeks every 8 weeks for a total of 2 years (i.e. for 12 cycles in total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Arsenic Trioxide Formulation</intervention_name>
    <description>Patients will be recruited to oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA) based-induction for 42 days. Daunorubicin (50mg/m^2/day for 3 days) will only be used during induction in patients &lt;65 with presenting white blood cell count (WBC) ≥ 10 x 10^9/L. In patients not receiving daunorubicin, hydroxyurea (2-4g/day) if WBC ≥ 5 x 10^9/L within the first 14 days of induction. A reassessment bone marrow aspirate will be performed on day 28 of induction for assessment of morphologic remission.&#xD;
Four weeks after the completion of induction phase, all patients, regardless of initial WBC, will receive two cycles of chemotherapy-free AAA consolidation (14 days every 28 days).&#xD;
Four weeks after completion of consolidation, all patients will receive 12 cycles of chemotherapy-free AAA maintenance (14 days every 8 week).</description>
    <arm_group_label>Oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA)</arm_group_label>
    <other_name>Arsenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed APL with t(15;17)(q24;q21) or acute myeloid leukaemia (AML) with&#xD;
             variant RARA translocation according to the World Health Organization (WHO)&#xD;
             Classification 2016&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Ability and willingness to comply with the study procedures and restrictions&#xD;
&#xD;
          4. Voluntary written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ECOG performance score &gt;2&#xD;
&#xD;
          2. Decompensated heart failure with left-ventricular ejection fraction of less than 40%&#xD;
             and global hypokinesia on echocardiogram.&#xD;
&#xD;
          3. Prolonged corrected QT interval (QTc) ≥ 500ms, in the absence of electrolyte&#xD;
             disturbances and medications known to prolong QTc&#xD;
&#xD;
          4. Significant liver function derangement (Bilirubin &gt; 3 times upper limit normal and/or&#xD;
             ALT &gt; 5 times upper limit of normal)&#xD;
&#xD;
          5. Glomerular filtration rate (GRF) by Cockcroft-Gault formula or eGFR (MDRD) of less&#xD;
             than 30mL/min&#xD;
&#xD;
          6. Female subject who is lactating or has positive pregnancy test result prior to the&#xD;
             first dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Gill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harry Gill, MD</last_name>
    <phone>+852 22554542</phone>
    <email>gillhsh@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Gill, MD</last_name>
      <phone>85222554542</phone>
      <email>gillhsh@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Yok-Lam Kwong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009 Dec 10;114(25):5126-35. doi: 10.1182/blood-2009-07-216457.</citation>
    <PMID>19797519</PMID>
  </reference>
  <reference>
    <citation>Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002 Dec 15;100(13):4298-302. Epub 2002 Aug 15.</citation>
    <PMID>12393590</PMID>
  </reference>
  <reference>
    <citation>Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, Ludwig WD, Staib P, Aul C, Grüneisen A, Kern W, Reichle A, Serve H, Berdel WE, Braess J, Spiekermann K, Wörmann B, Sauerland MC, Heinecke A, Hiddemann W, Hehlmann R, Büchner T; German AML Cooperative Group. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009 Dec;23(12):2248-58. doi: 10.1038/leu.2009.183. Epub 2009 Sep 10.</citation>
    <PMID>19741727</PMID>
  </reference>
  <reference>
    <citation>Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, Paoloni F, Fioritoni G, Ferrara F, Specchia G, Cimino G, Diverio D, Borlenghi E, Martinelli G, Di Raimondo F, Di Bona E, Fazi P, Peta A, Bosi A, Carella AM, Fabbiano F, Pogliani EM, Petti MC, Amadori S, Mandelli F; Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010 Oct 28;116(17):3171-9. doi: 10.1182/blood-2010-03-276196. Epub 2010 Jul 19.</citation>
    <PMID>20644121</PMID>
  </reference>
  <reference>
    <citation>Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009 Jun 1;27(16):2668-76. doi: 10.1200/JCO.2008.18.4119. Epub 2009 May 4.</citation>
    <PMID>19414681</PMID>
  </reference>
  <reference>
    <citation>Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999 Nov 15;94(10):3315-24.</citation>
    <PMID>10552940</PMID>
  </reference>
  <reference>
    <citation>Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 Sep 15;19(18):3852-60.</citation>
    <PMID>11559723</PMID>
  </reference>
  <reference>
    <citation>Au WY, Kumana CR, Kou M, Mak R, Chan GC, Lam CW, Kwong YL. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood. 2003 Jul 1;102(1):407-8.</citation>
    <PMID>12814916</PMID>
  </reference>
  <reference>
    <citation>Au WY, Li CK, Lee V, Yuen HL, Yau J, Chan GC, Ha SY, Kwong YL. Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients. Pediatr Blood Cancer. 2012 Apr;58(4):630-2. doi: 10.1002/pbc.23306. Epub 2011 Sep 2.</citation>
    <PMID>21898784</PMID>
  </reference>
  <reference>
    <citation>Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, Lau JS, Kwong YL. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood. 2011 Dec 15;118(25):6535-43. doi: 10.1182/blood-2011-05-354530. Epub 2011 Oct 12.</citation>
    <PMID>21998212</PMID>
  </reference>
  <reference>
    <citation>Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7. doi: 10.1073/pnas.0813280106. Epub 2009 Feb 18.</citation>
    <PMID>19225113</PMID>
  </reference>
  <reference>
    <citation>Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. Epub 2012 Jun 19.</citation>
    <PMID>22715121</PMID>
  </reference>
  <reference>
    <citation>Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874.</citation>
    <PMID>23841729</PMID>
  </reference>
  <reference>
    <citation>Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.</citation>
    <PMID>28003274</PMID>
  </reference>
  <reference>
    <citation>Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.</citation>
    <PMID>26384238</PMID>
  </reference>
  <reference>
    <citation>Gill H, Yim R, Lee HKK, Mak V, Lin SY, Kho B, Yip SF, Lau JSM, Li W, Ip HW, Hwang YY, Chan TSY, Tse E, Au WY, Kumana CR, Kwong YL. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study. Cancer. 2018 Jun 1;124(11):2316-2326. doi: 10.1002/cncr.31327. Epub 2018 Mar 26.</citation>
    <PMID>29579321</PMID>
  </reference>
  <reference>
    <citation>Gill H, Kumana CR, Yim R, Hwang YY, Chan TSY, Yip SF, Lee HKK, Mak V, Lau JSM, Chan CC, Kho B, Wong RSM, Li W, Lin SY, Lau CK, Ip HW, Leung RYY, Lam CCK, Kwong YL. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study. Cancer. 2019 Sep 1;125(17):3001-3012. doi: 10.1002/cncr.32180. Epub 2019 May 15.</citation>
    <PMID>31090936</PMID>
  </reference>
  <reference>
    <citation>Gill HS, Yim R, Kumana CR, Tse E, Kwong YL. Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators. Cancer. 2020 Jul 15;126(14):3244-3254. doi: 10.1002/cncr.32937. Epub 2020 May 4.</citation>
    <PMID>32365228</PMID>
  </reference>
  <reference>
    <citation>Kumana CR, Mak R, Kwong YL, Gill H. Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside. Front Oncol. 2020 Aug 4;10:1294. doi: 10.3389/fonc.2020.01294. eCollection 2020. Review.</citation>
    <PMID>32850403</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Promyelocytic Leukemia</keyword>
  <keyword>Oral Arsenic Trioxide</keyword>
  <keyword>Chemotherapy-free</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

